• Users Online: 655
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2019  |  Volume : 44  |  Issue : 4  |  Page : 208-217

Leukemia stem cell markers (CD 123 and CD25) are poor prognostic markers in patients with adult acute myeloid leukemia


1 Department of Clinical Pathology, Clinical Hematology and Bone Marrow Transplant Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2 Department of Internal Medicine, Clinical Hematology and Bone Marrow Transplant Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Correspondence Address:
Walaa A Elsalakawy
Department of Internal medicine, Clinical Hematology and Bone Marrow Transplant Unit, Faculty of Medicine, Ain Shams University, Cairo, 11241
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ejh.ejh_35_19

Rights and Permissions

Background Acute myeloid leukemia (AML) still remains a challenge for hematologists. Though an impressive number of prognostic factors have been identified in AML, it still ranks as one of the highest cancer-related deaths. Several studies have indicated its origin from a rare population of leukemic cells, known as leukemic stem cells, which initiate the disease and contribute to frequent relapses. Leucocyte interleukin-3 receptor α (CD123) and leukocyte interleukin-2 receptor α (CD25) are regarded as markers of leukemia stem cells. Aim The aim of this study was to investigate CD123 and CD25 expressions in newly diagnosed patients with AML by flow cytometry and correlate their expression with disease prognostic parameters and patients’ outcome at day 28 of therapy. Patients and methods This study was conducted on 30 newly diagnosed patients with AML admitted to Ain Shams University Hospitals. The expression of CD123 and CD25 was assessed, where gated blast cells were stained for CD45, CD38, CD34, CD123, and CD25. Results In the current study, CD123 was expressed in 13/30 (43.3%) patients, and CD25 was expressed in 4/30 (13.3%) patients. CD123 expression positively correlated with higher total leukocytic count and bone marrow blast percentage and CD25 expression. Both CD123 and CD25 expression had a significantly poor effect on outcome even in the good prognostic cytogenetic subgroups. Conclusion Results of our study clearly demonstrate the poor prognostic significance of CD123 and CD25 expression in patients with AML. This may represent an additional prognostic tool in risk-stratified management of patients with AML.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed96    
    Printed5    
    Emailed0    
    PDF Downloaded18    
    Comments [Add]    

Recommend this journal